<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906825</url>
  </required_header>
  <id_info>
    <org_study_id>22051-01</org_study_id>
    <nct_id>NCT03906825</nct_id>
  </id_info>
  <brief_title>Effect of CEAG on Inflammation and Endothelial Function</brief_title>
  <acronym>CEAG</acronym>
  <official_title>Acute Effects of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA (CEAG) on Inflammation and Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to look at the effect a dietary supplement called CEAG
      [Curcuminoids, EPA (Omega-3), Astaxanthin and Gamma Linolenic Acid (GLA)] has on inflammation
      and endothelial (inner layer of the blood vessels) function and whether it causes a lowering
      of blood pressure.The endothelium plays in an important role in blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is to assess the efficacy of Curcuminoids, EPA (Omega-3), Astaxanthin and
      GLA for improving inflammation and endothelial reactivity over a four week intervention
      period in individuals with metabolic syndrome. The study also examines the effect of
      Curcuminoids, EPA (Omega-3), Astaxanthin and GLA administration on other markers of
      cardiovascular function and cardiovascular disease risk including Total, LDL and
      HDL-Cholesterol, Triglycerides, and a multitude of inflammatory markers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">August 13, 2018</completion_date>
  <primary_completion_date type="Actual">August 13, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind Placebo Controlled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in inflammation at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Inflammatory markers IL-6, CRP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline of endothelial function</measure>
    <time_frame>4 weeks</time_frame>
    <description>endothelial function measured by brachial artery flow mediated dilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in cardio-metabolic relevant biomarkers</measure>
    <time_frame>4 weeks</time_frame>
    <description>Cardio-metabolic relevant biomarkers including fasting Lipids (mg/dL), Glucose (mg/dL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Inflammation</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>dietary supplement CEAG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dietary supplements consists of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA (CEAG).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Placebo does not contain any CEAG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CEAG</intervention_name>
    <description>Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA</description>
    <arm_group_label>dietary supplement CEAG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-75 years

          -  BP 121-140/81-90 mm Hg on average

          -  Body Mass Index (BMI) 18-40.

        Exclusion Criteria:

          -  free of chronic diseases including cancer or rheumatologic disorders

          -  weight in excess of 350 pounds

          -  bleeding disorder

          -  history of myocardial infarction or all types of revascularization procedures, second
             or third degree heart block with or without a pacemaker

          -  angina pectoris of any type

          -  concurrent potentially life-threatening arrhythmia or symptomatic arrhythmia
             clinically significant valvular heart disease

          -  history of malignancy of any organ system, treated or untreated, within the past 5
             years whether or not there is evidence of local recurrence or metastases, (with the
             exception of localized basal cell carcinoma of the skin)

          -  serum creatinine &gt; 2.0 mg/dl

          -  concurrent enrollment in another placebo-controlled trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Budoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew J. Budoff</investigator_full_name>
    <investigator_title>M.D;FACC</investigator_title>
  </responsible_party>
  <keyword>Endothelium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

